HUTCHMED (NASDAQ:HCM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of HUTCHMED (NASDAQ:HCM – Free Report) from a hold rating to a buy rating in a research report released on Saturday.

Several other equities research analysts have also recently weighed in on HCM. Morgan Stanley set a $13.60 price objective on HUTCHMED in a research report on Thursday, May 28th. Bank of America dropped their target price on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. The Goldman Sachs Group dropped their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, July 23rd. Finally, Weiss Ratings cut shares of HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $14.87.

Get HUTCHMED alerts:

Check Out Our Latest Analysis on HUTCHMED

HUTCHMED Stock Performance

NASDAQ HCM opened at $12.55 on Friday. The stock has a 50-day simple moving average of $11.04 and a 200 day simple moving average of $13.05. HUTCHMED has a twelve month low of $9.77 and a twelve month high of $18.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.50.

HUTCHMED (NASDAQ:HCM – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The business had revenue of $139.14 million during the quarter, compared to analysts’ expectations of $304.16 million. On average, research analysts forecast that HUTCHMED will post 0.23 EPS for the current fiscal year.

Institutional Trading of HUTCHMED

Several institutional investors have recently modified their holdings of the company. Ameriprise Financial Inc. increased its position in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares during the period. Bank of America Corp DE lifted its position in HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after purchasing an additional 3,035 shares during the period. Dimensional Fund Advisors LP lifted its position in HUTCHMED by 34.2% in the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after purchasing an additional 5,538 shares during the period. Janney Montgomery Scott LLC acquired a new stake in HUTCHMED during the first quarter worth $365,000. Finally, BNP Paribas Financial Markets boosted its stake in HUTCHMED by 19.7% during the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock worth $377,000 after buying an additional 4,116 shares in the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

(Get Free Report)

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.

Recommended Stories

• Five stocks we like better than HUTCHMED
• SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
• 3 Dividend Champion Utilities for a Market That Can’t Sit Still
• These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
• First Solar’s Profit Engine Faces a New Policy Test in Washington

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.